EUS-GUIDED TISSUE ACQUISITION FOR PANCREATIC CANCER IN THE ERA OF GENOMIC MEDICINE

Abstract

In recent years, cancer genomic medicine centered on comprehensive genomic profiling (CGP) has been widely practiced in the field of pancreatic cancer. EUS-guided tissue acquisition (EUS-TA) has played an important role in pancreatic cancer diagnosis, and recently, more tissue samples for CGP testing are required for EUS-TA.

To perform a CGP test, it is desirable to know the following: the differences between the CGP tests approved by insurance in Japan (the OncoguideTMNCC Oncopanel System (NCCOP) and the Foundation One CDx Cancer Genome Profile (F-One); the required analysis criteria; the needle selection method to meet these criteria as much as possible; and the target of puncture. In addition, it is important to understand both specimen collection and processing to increase the success rate of the CGP test. The field of cancer genomic medicine is expected to enter an era of increasing turbulence in the future, and endoscopists must respond flexibly to these changes.